## Inhaled Corticosteroid with Lowest Systemic Bioavailability in Children **Key Point:** Ciclesonide has the lowest systemic bioavailability (0.3%) among all inhaled corticosteroids due to its unique pro-drug formulation, making it the safest choice for pediatric patients concerned about growth suppression. ### Mechanism of Ciclesonide's Safety Advantage **High-Yield:** Ciclesonide is a **pro-drug** that undergoes activation only in the lungs by esterase enzymes. The inactive parent compound is swallowed and undergoes rapid hepatic metabolism, resulting in negligible systemic exposure. | ICS | Systemic Bioavailability | Pro-drug? | Lung Deposition | Pediatric Safety | |-----|-------------------------|-----------|-----------------|------------------| | Ciclesonide | 0.3% (lowest) | Yes | 52% (highest) | Excellent | | Fluticasone propionate | 1% | No | 15–20% | Good | | Beclomethasone | 5–10% | No | 5–10% | Moderate | | Budesonide | 10–15% | No | 20–25% | Moderate | **Clinical Pearl:** Ciclesonide's combination of high lung deposition (52%) and ultra-low systemic bioavailability (0.3%) makes it uniquely suited for pediatric asthma, where minimizing HPA-axis suppression and growth velocity changes is paramount. ### Evidence for Growth Safety **Mnemonic:** **CICLE = Clever, Inactive, Converted Locally, Low systemic exposure, Excellent pediatric choice** — remember ciclesonide as the pro-drug with the safest systemic profile. Longitudinal pediatric studies have demonstrated that ciclesonide causes minimal or no measurable reduction in growth velocity compared to other ICS at equipotent doses. This makes it the preferred ICS in children with parental anxiety about systemic steroid effects. **Tip:** In pediatric asthma questions, if the stem emphasizes "growth concern," "systemic absorption," or "HPA-axis suppression," ciclesonide is the answer. Its pro-drug mechanism is a high-yield concept for NEET PG.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.